- Verrica Pharmaceuticals (NASDAQ:VRCA) announces that its new drug application for a proprietary topical therapy for the treatment of molluscum contagiosum has been accepted by the FDA.
- The company says the PDUFA goal date assigned by the FDA for the NDA on VP-102 is July 13, 2020.
- Management calls the acceptance of the NDA for review the next step toward bringing patients and their caregivers a safe and effective topical therapy for the common, highly contagious viral skin disease.
- Source: Press Release